Anika Therapeutics, Inc. (ANIK) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Anika Therapeutics, Inc. (ANIK) closed at USD 20.25 on 2026-10-14, a change of +107.9 % over the past year, with a market capitalization of USD 276.89M.

Anika Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Anika Therapeutics, Inc. key figures

Previous close

USD 20.25 (2026-10-14)

1-year change

+107.9 %

Market cap

USD 276.89M

Enterprise value

USD 263.73M

P/E ratio (trailing)

-89.96

P/E ratio (forward)

21.78

EPS (trailing)

-0.23

EPS (forward)

0.95

PEG ratio

2.13

Price to book

2.02

Revenue growth

15.6 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.53

Employees

235

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Anika Therapeutics, Inc. and compare it with other stocks.